Search results for "carbapenem"

showing 10 items of 50 documents

Antibiotic treatment of infections caused by carbapenem-resistant Gram-negative bacilli: an international ESCMID cross-sectional survey among infecti…

2018

ESGAP, ESGBIS, ESGIE and the CRGNB treatment survey study group.

0301 basic medicineAcinetobacter baumanniiCarbapenemAntibioticsDrug ResistanceDrug resistanceTigecyclineAcinetobacter baumannii; Carbapenem; Carbapenem-resistant Gram-negative bacilli; Combination therapy; Enterobacteriaceae; Polymyxin; Pseudomonas aeruginosa; SurveyPolymyxin0302 clinical medicineSurveys and Questionnairespolycyclic compounds030212 general & internal medicineAcinetobacter baumannii; Carbapenem; Carbapenem-resistant Gram-negative bacilli; Combination therapy; Enterobacteriaceae; Polymyxin; Pseudomonas aeruginosa; Survey; Anti-Bacterial Agents; Carbapenems; Cross Infection; Cross-Sectional Studies; Drug Resistance Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Hospitals; Humans; Microbial Sensitivity Tests; Surveys and QuestionnairesSurveyCarbapenemAcinetobacter baumannii; Carbapenem; Carbapenem-resistant Gram-negative bacilli; Combination therapy; Enterobacteriaceae; Polymyxin; Pseudomonas aeruginosa; Survey; Anti-Bacterial Agents; Carbapenems; Cross Infection; Cross-Sectional Studies; Drug Resistance Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Hospitals; Humans; Microbial Sensitivity Tests; Surveys and Questionnaires; Microbiology (medical); Infectious DiseasesCross InfectionbiologyMicrobial Sensitivity TestCarbapenem-resistant Gram-negative bacilliBacterialantibiotic management carbapenem-resistant Gram-negative bacteriaGeneral MedicineHospitals3. Good healthAcinetobacter baumanniiAnti-Bacterial AgentsInfectious DiseasesPseudomonas aeruginosamedicine.drugHumanMicrobiology (medical)medicine.medical_specialtymedicine.drug_class030106 microbiologyMicrobial Sensitivity TestsFosfomycincarbapenem-resistant Gram-negative bacteria03 medical and health sciencesHospitalEnterobacteriaceaeInternal medicineAnti-Bacterial AgentDrug Resistance BacterialGram-Negative BacteriamedicineGram-Negative Bacterial InfectionHumansCombination therapyCross-Sectional Studiebusiness.industrybiochemical phenomena metabolism and nutritionbiology.organism_classificationbacterial infections and mycosesCross-Sectional StudiesCarbapenemsInfectious disease (medical specialty)Carbapenem-resistant gram-negative bacilli[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieantibiotic managementbusinessGram-Negative Bacterial InfectionsRifampicin
researchProduct

Co-existence of virulence factors and antibiotic resistance in new Klebsiella pneumoniae clones emerging in south of Italy

2018

Abstract Background Endemic presence of Klebsiella pneumoniae resistant to carbapenem in Italy has been due principally to the clonal expansion of CC258 isolates; however, recent studies suggest an ongoing epidemiological change in this geographical area. Methods 50 K. pneumoniae strains, 25 carbapenem-resistant (CR-Kp) and 25 susceptible (CS-Kp), collected from march 2014 to march 2016 at the Laboratory of Bacteriology of the Paolo Giaccone Polyclinic University hospital of Palermo, Italy, were characterized for antibiotic susceptibility and fully sequenced by next generation sequencing (NGS) for the in silico analysis of resistome, virulome, multi-locus sequence typing (MLST) and core sin…

0301 basic medicineAdultKlebsiellaGenotypeKlebsiella pneumoniae030106 microbiologyVirulenceYersiniabactinPolymorphism Single Nucleotidebeta-Lactamaseslcsh:Infectious and parasitic diseasesMicrobiology03 medical and health scienceschemistry.chemical_compoundBacterial ProteinsGenotypeDrug Resistance BacterialHumanslcsh:RC109-216TypingSicilyPhylogenyAgedAged 80 and overbiologyVirulence factorsMiddle Agedbiology.organism_classificationAnti-Bacterial AgentsBacterial Typing TechniquesKlebsiella InfectionsKlebsiella pneumoniae030104 developmental biologyInfectious DiseaseschemistryCarbapenemsCarbapenem-resistant Klebsiella pneumoniaeMultilocus sequence typingAerobactinMultilocus Sequence TypingResearch Article
researchProduct

Resistance profiles and risk factors of resistant microorganisms in bacteraemia of abdominal origin

2017

Abstract Objective The presence of resistant microorganisms is a major cause of failure in initial empirical antimicrobial therapy. The objectives of this study are to determine the resistance profile of microorganisms that cause bacteraemia of abdominal origin and to identify whether the previous use of antibiotics and the place of acquisition of bacteraemia are risk factors associated with the presence of resistant organisms. Material and methods A clinical, observational, epidemiological, retrospective cohort study was conducted with all the adult patients admitted to a university hospital from 2011 to 2013. Antimicrobial resistance profiles were described and a 95% confidence interval c…

0301 basic medicineCarbapenembiologybusiness.industrymedicine.drug_class030106 microbiologyAntibioticsGeneral Medicinebacterial infections and mycosesmedicine.disease_causeAntimicrobialbiology.organism_classificationCandida parapsilosisMethicillin-resistant Staphylococcus aureusMicrobiology03 medical and health scienceschemistry.chemical_compoundAntibiotic resistancechemistryCandida kruseiLinezolidmedicinebusinessmedicine.drugRevista Española de Anestesiología y Reanimación (English Edition)
researchProduct

Ceftazidime-Avibactam Combination Therapy Compared to Ceftazidime-Avibactam Monotherapy for the Treatment of Severe Infections Due to Carbapenem-Resi…

2020

Ceftazidime-avibactam (CZA) is a novel beta-lactam beta-lactamase inhibitor combination approved for the treatment of complicated urinary tract infections, complicated intra-abdominal infections, and for hospital-acquired/ventilator-associated pneumonia. The aim of this systematic review (PROSPERO registration number: CRD42019128927) was to evaluate the effectiveness of CZA combination therapy versus CZA monotherapy in the treatment of severe infections. The databases included in the search, until February 12th, 2020, were MEDLINE by PubMed, EMBASE, and The Cochrane Central Register of Controlled Trials. We included both randomized controlled trials (RCTs) and non-randomized studies publish…

0301 basic medicineCarbapenem-resistant enterobacteriaceaeBiochemistrylaw.inventionsepsisCeftazidime‐avibactam0302 clinical medicineRandomized controlled trialsystematic reviewlawPharmacology (medical)030212 general & internal medicineGeneral Pharmacology Toxicology and Pharmaceuticsnetwork meta-analysisceftazidime-avibactamAnti‐infective agentnetwork meta-analysiInfectious Diseasescarbapenem-resistant EnterobacteriaceaeMeta-analysisβ-lactamase inhibitors.sepsimedicine.drugMicrobiology (medical)medicine.medical_specialtyCombination therapyβ-lactamase inhibitors030106 microbiologyMEDLINEβ‐lactamase inhibitorsMicrobiologyArticle03 medical and health sciencesCarbapenem‐resistant Enterobacteriaceaemultidrug resistanceInternal medicinemedicineanti-infective agentbacteremiabusiness.industrylcsh:RM1-950Retrospective cohort studyCeftazidime/avibactammedicine.diseaseinfectionlcsh:Therapeutics. PharmacologyBacteremiaanti-infective agentsbusinessNetwork meta‐analysi
researchProduct

Rapid detection of carbapenem resistance: Targeting a zero level of inadequate empiric antibiotic exposure

2016

Resistance to carbapenems is an increasingly encountered phenomenon in the ICU, complicating empiric and targeted antimicrobial therapy. Infections due to carbapenem-resistant microorganisms are characterized by high morbidity and mortality [1, 2]. Recently, there has been an increasing interest in rapid detection techniques, based on real time on-demand easy-to-use PCR, to detect genes responsible for carbapenem resistance. One of these techniques is the Cepheid Xpert Carba-R assay, which is able to detect and differentiate five of the most frequent genes associated with non-susceptibility to carbapenems in Gram-negative bacteria (bla KPC, bla VIM, bla OXA-48, bla IMP-1, bla NDM). The diag…

0301 basic medicineGram-negative bacteriaLetterCarbapenem resistanceMultidrug-resistant bacteria030106 microbiologyDrug ResistanceDrug resistanceCritical Care and Intensive Care MedicineMicrobiologylaw.invention03 medical and health sciences0302 clinical medicinelawGram-Negative Bacteriapolycyclic compoundsMedicineInfection controlHumansCarbapenem resistance; Multidrug-resistant bacteria; Polymerase chain reaction; Critical Care and Intensive Care MedicinePolymerase chain reactionCarbapenem resistancebiologybusiness.industryOutbreak030208 emergency & critical care medicinebiochemical phenomena metabolism and nutritionbacterial infections and mycosesbiology.organism_classificationAntimicrobialPolymerase chain reactionIntensive Care UnitsCarbapenemsEtiologyCarbapenem resistance; Multidrug-resistant bacteria; Polymerase chain reactionbusiness
researchProduct

Which non-carbapenem antibiotics are active against extended-spectrum β-lactamase-producing Enterobacteriaceae?

2018

In this study, the activity of 18 non-carbapenem antibiotics was evaluated against 100 extended-spectrum β-lactamase (ESBL)-producing Escherichia coli (ESBL-Ec) and 50 ESBL-producing Klebsiella pneumoniae (ESBL-Kp) isolated from urinary tract infections and bacteraemia in 2016. Minimum inhibitory concentrations (MICs) were determined using reference methods and the susceptibility profiles were defined according to European Committee on Antimicrobial Susceptibility Testing (EUCAST) 2017 recommendations. All of the ESBL-Ec isolates were susceptible to ceftazidime/avibactam and a great majority of them were susceptible to fosfomycin (98%), piperacillin/tazobactam (97%), amikacin (97%) and nitr…

0301 basic medicineKlebsiella pneumoniaePenicillanic AcidCeftazidimeCeftazidimechemistry.chemical_compoundAntibiotics[ SDV.MP ] Life Sciences [q-bio]/Microbiology and Parasitologypolycyclic compoundsPharmacology (medical)biologyEnterobacteriaceae InfectionsGeneral MedicineAnti-Bacterial Agents3. Good healthDrug CombinationsKlebsiella pneumoniaeInfectious Diseases[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyAmikacinUrinary Tract InfectionsCeftolozanemedicine.drugMicrobiology (medical)TazobactamAvibactam030106 microbiologyMicrobial Sensitivity TestsTazobactambeta-LactamasesMicrobiology03 medical and health sciencesEnterobacteriaceaemedicineEscherichia coliHumansMecillinambusiness.industrybiochemical phenomena metabolism and nutritionbiology.organism_classificationbacterial infections and mycosesCephalosporinsAlternativesCarbapenemschemistryESBLSusceptibilitybacteriabusinessAzabicyclo CompoundsPiperacillin
researchProduct

Use of Cepheid Xpert Carba-R® for Rapid Detection of Carbapenemase-Producing Bacteria in Abdominal Septic Patients Admitted to Intensive Care Unit.

2016

Abstract Early institution of effective antibiotic therapy and source control are pivotal to improve survival of abdominal septic patients. Xpert® Carba-R is a real time polymerase chain reaction assay for rapid detection and differentiation of five genes (blaKPC, blaVIM, blaOXA-48, blaIMP-1, blaNDM) responsible for carbapenem resistance. We performed an observational study investigating the clinical usefulness and applicability of Xpert® Carba-R to detect carbapenem resistance in abdominal septic patients admitted to intensive care unit. We compared the results of Xpert® Carba-R with standard microbiological culture. We collected a set of two rectal/stomia swabs and two swabs from abdomina…

0301 basic medicineMaleMicrobiological cultureAntibioticslcsh:MedicineArtificial Gene Amplification and ExtensionPathology and Laboratory MedicinePolymerase Chain Reactionlaw.inventionKlebsiella Pneumoniae0302 clinical medicinelawAntibioticsKlebsiellaEpidemiologymultidrug resistance sepsis intensive care unitAbdomenMedicine and Health SciencesMedicine030212 general & internal medicinelcsh:ScienceMultidisciplinaryAntimicrobialsCepheid Xpert Carba-R®DrugsMicrobial CulturesMiddle AgedIntensive care unitHospitalsBacterial PathogensIntensive Care UnitsAbdominal SurgeryMedical MicrobiologyFemaleBiological CulturesPathogensResearch ArticleDNA Bacterialmedicine.medical_specialtymedicine.drug_class030106 microbiologySurgical and Invasive Medical ProceduresResearch and Analysis MethodsReal-Time Polymerase Chain ReactionRapid detectionMicrobiologySensitivity and Specificitybeta-Lactamases03 medical and health sciencesAntibiotic resistanceBacterial ProteinsEnterobacteriaceaeDiagnostic MedicineInternal medicineIntensive careMicrobial ControlSepsisDrug Resistance BacterialHumansMED/41 - ANESTESIOLOGIAMolecular Biology TechniquesMicrobial PathogensMolecular BiologyAgedPharmacologyBacteriabusiness.industrylcsh:ROrganismsRectumBiology and Life SciencesSurgeryHealth CareCarbapenemsHealth Care FacilitiesAntibiotic Resistancelcsh:QAntimicrobial ResistanceReagent Kits DiagnosticbusinessAbdominal surgery
researchProduct

Erratum for Yahav et al., "New β-Lactam-β-Lactamase Inhibitor Combinations".

2021

The limited armamentarium against drug-resistant Gram-negative bacilli has led to the development of several novel β-lactam–β-lactamase inhibitor combinations (BLBLIs). In this review, we summarize their spectrum of in vitro activities, mechanisms of resistance, and pharmacokinetic-pharmacodynamic (PK-PD) characteristics. A summary of available clinical data is provided per drug. Four approved BLBLIs are discussed in detail. All are options for treating multidrug-resistant (MDR) Enterobacterales and Pseudomonas aeruginosa. Ceftazidime-avibactam is a potential drug for treating Enterobacterales producing extended-spectrum β-lactamase (ESBL), Klebsiella pneumoniae carbapenemase (KPC), AmpC, a…

0301 basic medicineMicrobiology (medical)General Immunology and MicrobiologyCarbapenem resistantbiologyEpidemiologyChemistryStereochemistryKlebsiella pneumoniae030106 microbiologyPublic Health Environmental and Occupational HealthReviewbiochemical phenomena metabolism and nutritionbiology.organism_classificationbacterial infections and mycoses03 medical and health scienceschemistry.chemical_compound030104 developmental biologyInfectious Diseasesβ lactamase inhibitorLactampolycyclic compoundsbacteriaClinical microbiology reviews
researchProduct

Outbreak of ST395 KPC-Producing Klebsiella pneumoniae in a Neonatal Intensive Care Unit in Palermo, Italy

2018

0301 basic medicineMicrobiology (medical)Klebsiella pneumoniae Neonatal Intensive Care Unit Carbapenem resistance KPC Outbreakmedicine.medical_specialtyNeonatal intensive care unitEpidemiologyKlebsiella pneumoniae030106 microbiologySettore MED/42 - Igiene Generale E Applicatabeta-Lactam ResistanceDisease Outbreaks03 medical and health sciencesIntensive Care Units NeonatalmedicineHumansBacteriological TechniquesInfection ControlbiologyOutbreakbiology.organism_classificationKlebsiella InfectionsKlebsiella pneumoniae030104 developmental biologyInfectious DiseasesCarbapenemsItalyEmergency medicineBeta lactam antibiotics
researchProduct

Draft genome sequence and biofilm production of a carbapenemase-producing Klebsiella pneumoniae (KpR405) sequence type 405 strain isolated in Italy

2021

Rapid identification and characterization of multidrug-resistant Klebsiella pneumoniae strains is essential to diagnose severe infections in patients. In clinical routine practice, K. pneumoniae is frequently identified and characterized for outbreak investigation. Pulsed-field gel electrophoresis or multilocus sequence typing could be used, but, unfortunately, these methods are time-consuming, laborious, expensive, and do not provide any information about the presence of resistance and virulence genes. In recent years, the decreasing cost of next-generation sequencing and its easy use have led to it being considered a useful method, not only for outbreak surveillance but also for rapid ide…

0301 basic medicineMicrobiology (medical)Klebsiella pneumoniae<i>Klebsiella pneumoniae</i>030106 microbiologyVirulenceRM1-950BiochemistryMicrobiologyMicrobiologyCarbapenemase03 medical and health sciencesPharmacology (medical)General Pharmacology Toxicology and PharmaceuticsPathogenWhole genome sequencingbiologyBiofilmBiofilmOutbreakST405biology.organism_classificationKlebsiella pneumoniae030104 developmental biologyInfectious DiseasesMultilocus sequence typingTherapeutics. PharmacologyBacteria
researchProduct